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Yates and De Luca’s commentary on our recent article highlights an interesting point that 
we did not address in our work: That age may diminish the effects genetic factors have on 
pathology in multiple sclerosis (MS). It also reveals a citation error in our article, where we 
reference the group’s earlier work on the spinal cord1 in place of their more recent findings 
in the motor cortex.2 
 
Given the relatively low number of people included in our magnetic resonance imaging 
(MRI) study (n=85; 30 RRMS, 30 SPMS, 25 PPMS), we were wary of undertaking 
subgroup analysis. However, as in the study by Yates and colleagues2, we have now split 
the cohort around their median age (in our study 50 years; range 21-65). In neither the 
younger (n=38; Table 1) or older group (n=47; Table 2) - or the whole group3 - were MRI 
measures of cortical pathology (lesion and grey matter volumes, and magnetization 
transfer ratios) significantly more abnormal in HLA-DRB*1501 positive than negative MS 
groups. We note that Yates et al. (2015), similarly did not find a difference in the extent of 
cortical demyelination in the whole cohort, but did find one in the younger group.2 
 
Both studies are likely to be underpowered, and with regard to the age related findings 
both are reliant on small subgroup analyses (n=38 in our study, of whom 17 were HLA-
DRB*1501 positive, and n=23 in the Yates et al. study, of whom 8 were positive). We are 
also cautious when trying to compare these studies directly due to clear - and potentially 
relevant - differences in the cohorts. The subgroup assessed by Yates et al. includes more 
than double the proportion of people with progressive MS (87% compared with 39% in our 
subgroup analysis) (Table 3). As such the cohort included in our study is more 
representative of people living with relapsing-remitting MS, and that included in the Yates 
et al. study weighted towards people with progressive MS who have died relatively young. 
A unifying explanation could be that some people who are HLA-DRB*1501 positive run a 
more aggressive early course, and so are less likely to be part of an MRI cohort but more 
likely to be included in a post mortem study. Further work, in independent cohorts, is 
required to clarify this. Ideally this would include people who have recently had a clinically 
isolated syndrome suggestive of MS or who have clinically early MS. 
 
We fully agree with Yates and De Luca that there is great potential for histopathology and 
MRI studies to provide complementary data, each playing to their strengths. For example, 
as they note, histopathological studies are much better able to detect cortical lesions than 
is currently possible with MRI4, and so it should be possible to detect associations - where 
present - between cortical lesions and genetics factors in smaller cohorts. However, 
histopathology studies have to make use of the material available to them, and so are 
usually relatively skewed towards older people with progressive MS. Here MRI studies 
may bridge the gap, albeit requiring more people to detect equivalent associations when 
compared with histopathological studies, and also allow links between pathology and 
clinical features to be looked for. 
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Table 1: Patient characteristics and MRI measures in 38 patients younger than the median 
age of the whole MS population (50 years). 
 
Measure HLA-DRB*1501 P - value 
 Pos Neg Unadjusted Adjusted 
N 17/38 21/38 NA NA 
Disease duration (years) 13.4±7.9 8.7±4.9 0.03 NA 
Age (years) 38.4±6.8 40.5±7.6 0.36 NA 
Female 9(53%) 10(48%) 0.74§ NA 
BPF (%) 80.9±2.3 79.8±2.6 0.2 0.24 
GMF (%) 47.8±1.2 47.6±1.3 0.58 0.88 
Intracortical lesion volume 
(ml) 
0.49±0.24 0.54±0.52 0.73 0.4 
Leukocortical lesion 
volume (ml) 
0.55±0.63 0.70±1.19 0.61 0.23 
MTR intracortical lesions 31.2±1.8 30.9±2.2 0.64 0.64 
MTR leukocortical lesions 29.9±2.9 28.5±3.5 0.26 0.28 
MTR normal-appearing 
cortical grey matter 
31.9±1.1 31.0±1.5 0.08 0.16 
 
 
 
 
P values are given unadjusted and adjusted for gender, age, disease duration, current and 
previous disease modifying treatment and smoking status (GLM, confirmed by bootstrap 
analysis, case resampling n=1000). §Chi Square Test 
 
Table 2: Patient characteristics and MRI measures in 47 patients with the age of 50 or 
higher. 
 
Measure HLA-DRB*1501 P - value 
 Pos Neg Unadjusted Adjusted 
N 25/47 22/47 NA NA 
Disease duration (years) 22.5±11.5 19.2±9.7 0.3 NA 
Age (years) 57.9±4.4 56.9±4.8 0.48 NA 
Female 18 (82%) 15 (60%) 0.78§ NA 
BPF (%) 79.8±1.2 79.2±1.8 0.16 0.16 
GMF (%) 46.5±0.8 46.5±1.7 0.42 0.75 
Intracortical lesion 
volume (ml) 
0.42±0.29 0.39±0.53 0.78 0.48 
Leukocortical lesion 
volume (ml) 
0.41±0.37 0.61±0.76 0.25 0.82 
MTR intracortical lesions 30.5±2.0 29.8±3.2 0.27 0.13 
MTR leukocortical 
lesions 
28.7±3.2 28.1±2.9 0.48 0.51 
MTR normal-appearing 
cortical grey matter 
31.0±1.3 30.8±0.9 0.63 0.44 
 
P values are given unadjusted and adjusted for gender, age, disease duration, current and 
previous disease modifying treatment and smoking status (GLM, confirmed by bootstrap 
analysis, case resampling n=1000). §Chi Square Test 
Table 3: Demographics of the young* patients in both publications2,3 
 
Parameter Yaldizli et al. 2016 Yates et al. 2015 
N 38 23 
Mean Age in years (range) 39.6 (range: 21-49) 52 (range: 40-60) 
Mean Disease duration in 
years (range) 
10.8 (range: 1.6-31) 25 (range: 16-38) 
Female 50% 74% 
HLA-DRB*1501 positive  17/38 8/23 
Progressive MS 39% 87% 
 
Note: *young was defined as age lower than the median of the whole study population 
